relatlimab relatlimab relatlimab is a monoclonal antibody designed for the treatment of melanoma. it is used in combination with nivolumab to treat melanoma. relatlimabmonoclonal antibodytypewhole antibodysourcehumantargetlymphocyte activation gene-3 (lag-3)clinical dataother namesbms-986016, relatlimab-rmbwlicense data us dailymed: relatlimab routes ofadministrationintravenousdrug classantineoplasticatc codenonelegal statuslegal status us: ℞-only only in combination with nivolumab identifierscas number1673516-98-7drugbankdb14851uniiaf75xof6w3keggd11350chemical and physical dataformulac6472h9922n1710o2024s38molar mass145288.79 g·mol−1 relatlimab is a lymphocyte activation gene-3 (lag-3) inhibitor. it is under development by bristol-myers squibb. it is made using chinese hamster ovary cells. history as of 2018, relatlimab is undergoing phase ii/iii trials. the combination nivolumab/relatlimab (opdualag) was approved for medical use in the united states in march 2022. names relatlimab is the united states adopted name (usan) and the international nonproprietary name (inn).